Health Must Be At Center Of Post-Brexit Relationship, Say Industry & NHS Bodies
Executive Summary
UK industry and National Health Service bodies say that the “political declaration” on the future UK-EU relationship fails to address key public health issues such as regulatory cooperation, collaboration in science and innovation, and tackling counterfeit medicines.
You may also be interested in...
Brexit Declaration Offers Scant Comfort On Future UK-EU Regulatory Links
EU leaders have endorsed the “political declaration” outlining the aspirations for the future relationship between the UK and the EU after Brexit, together with the much larger withdrawal deal. The life sciences industry will be disappointed that in the drug regulatory area the political declaration contains little beyond an aspiration for “possible” cooperation between the UK drug regulator and the European Medicines Agency.
UK Pharma Takes Hope From Draft Brexit Deal But Uncertainty Reigns
The Brexit deal agreed by UK ministers brings little certainty for the life sciences sector. Moreover, the related and unprecedented political instability means that its final approval is far from guaranteed.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.